2013/1 GaBI Journal Table of Contents

Contents

Editor’s Letter

Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal

Letters to the Editor

The ethics of biosimilars

Austria increases dialogue in order to involve physicians more with biosimilars

Editorial

Health authority perspective on biosimilars

Commentary

The case for biosimilars–a payer’s perspective

Original Research

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation

Review Article

Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act

Current status of biopharmaceuticals in Iran’s pharmaceutical market

Biosimilars in the European market

Perspective

The future of biological therapy: a pathway forward for biosimilars

Regulatory

PMDA update: the current situation and future directions

Guidelines

New CHMP guideline on immunogenicity of monoclonal antibodies

EORTC continues to support the appropriate treatment of adult patients with G-CSF to prevent febrile neutropenia: guideline updates

Abstracted Scientific Content

Alleviating concerns around generic antiepileptic medications

Pharma News

‘Similar biologics’ approved and marketed in India

For Patients

IAPO launched the Patient-Centred Healthcare Indicators Review

Source URL: https://gabi-journal.net/2400.html